Lazertinib
![]() | |
Clinical data | |
---|---|
Trade names | Lazcluze, Leclaza |
License data |
|
Routes of administration | By mouth |
Drug class | EGFR inhibitor |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C30H34N8O3 |
Molar mass | 554.655 g·mol−1 |
3D model (JSmol) | |
| |
|
Lazertinib, sold under the brand name Lazcluze and Leclaza, is an anti-cancer medication used for the treatment of non-small cell lung cancer.[1][2][3] It is a kinase inhibitor of epidermal growth factor receptor.[1]
The most common adverse reactions include rash, nail toxicity, infusion-related reactions (amivantamab), musculoskeletal pain, edema, stomatitis, venous thromboembolism, paresthesia, fatigue, diarrhea, constipation, COVID-19 infection, hemorrhage, dry skin, decreased appetite, pruritus, nausea, and ocular toxicity.[2]
Lazertinib was approved for medical use in South Korea in January 2021,[4][5] and in the United States in August 2024.[2][6]
Medical uses
[edit]Lazertinib is indicated in combination with amivantamab for the first-line treatment of adults with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations.[2]
History
[edit]Efficacy was evaluated in MARIPOSA (NCT04487080), a randomized, active-controlled, multicenter trial of 1074 participants with exon 19 deletion or exon 21 L858R substitution mutation-positive locally advanced or metastatic non-small cell lung cancer and no prior systemic therapy for advanced disease.[2] Participants were randomized (2:2:1) to receive lazertinib in combination with amivantamab, osimertinib monotherapy, or lazertinib monotherapy (an unapproved regimen for non-small cell lung cancer) until disease progression or unacceptable toxicity.[2]
Society and culture
[edit]Legal status
[edit]Lazertinib was approved for medical use in the United States in August 2024.[2]
Names
[edit]Lazertinib is the international nonproprietary name.[7]
References
[edit]- ^ a b c "Lazcluze- lazertinib tablet, film coated". DailyMed. 20 August 2024. Retrieved 5 September 2024.
- ^ a b c d e f g "FDA approves lazertinib with amivantamab-vmjw for non-small lung cancer". U.S. Food and Drug Administration (FDA). 19 August 2024. Retrieved 21 August 2024.
This article incorporates text from this source, which is in the public domain.
- ^ Dhillon S (June 2021). "Lazertinib: First Approval". Drugs. 81 (9): 1107–1113. doi:10.1007/s40265-021-01533-x. PMC 8217052. PMID 34028784.
- ^ "Yuhan wins approval as MFDS clear T790M EGFR TKI drug 'Lazertinib'". 바이오스펙테이터. Retrieved 23 August 2024.
- ^ Dhillon S (2021). "Lazertinib: First Approval". Drugs. 81 (9): 1107–1113. doi:10.1007/s40265-021-01533-x. ISSN 0012-6667. PMC 8217052. PMID 34028784.
- ^ "Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer". Johnson & Johnson (Press release). 20 August 2024. Retrieved 21 August 2024.
- ^ World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 79". WHO Drug Information. 32 (1). hdl:10665/330941.
External links
[edit]- Clinical trial number NCT04487080 for "A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA)" at ClinicalTrials.gov